Urinary tract infection (UTI) is among the most common community-acquired infections, and it has a very high rate of recurrence. Of women diagnosed with UTI, 35% to 53% have a recurrence within 12 months. The standard treatment for UTI is a course of antibiotics; however, there is not a standard prophylactic treatment for recurrent UTI. Now that the relationship is understood between overuse of antibiotics and the development of multidrug-resistant strains within microbial populations, the authors argue that it is imperative to develop a long-term standard preventive therapy for recurrent UTI.

In this prospective, non-randomized phase II clinical trial, researchers at the Department of Urology at the Santa Chiara Regional Hospital in Trento, Italy evaluated a combination of natural therapy for recurrent UTI. The product is produced by Anatek Health Italia, Milan, Italy, and is sold under the name AVIUR Retard. Each tablet contains the following combination of proprietary products:…